期刊
BIOMARKERS IN BRAIN DISEASE
卷 1180, 期 -, 页码 36-46出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2009.05064.x
关键词
Alzheimer's disease; proteomics; biomarkers; CFH; A2M; plasma
资金
- EU
- Alzheimer's Research Trust
- NIHR Specialist Biomedical Research Centre for Mental Health at the South London
- Maudsley NHS Foundation Trust
- King's College London, Institute of Psychiatry, London, United Kingdom
There is an urgent need for Alzheimer's disease (AD) biomarkers especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. We report here the development and design of AddNeuroMed and the progress toward the development of plasma markers. Despite the obstacles to such markers, we have identified a range of markers including CFH and A2M, both of which have been independently replicated. The experience of AddNeuroMed leads us to three overall conclusions. First, collaboration is essential. Second, design is paramount and combining modalities, such as imaging and proteomics, may be informative. Third, animal models are valuable in biomarker research. Most importantly, we have learned that plasma markers are feasible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据